Biosphere Bags $9M DoD Grant for Air-Based Protein Bioreactors

Biosphere, a California-based innovator in biomanufacturing technology, has been awarded a significant $9 million grant from the U.S. Department of Defense (DoD). This funding, spread over 3.5 years, will accelerate the development of novel, portable bioreactors capable of producing protein directly from atmospheric gases. This strategic investment underscores the DoD's growing interest in decentralized and resilient biomanufacturing capabilities, particularly for applications in challenging operational environments where traditional supply chains may be compromised.

The core of Biosphere's innovation lies in its proprietary UV-sterilization technology for bioreactors. Unlike conventional methods that rely on energy-intensive and complex steam-in-place (SIP) systems, Biosphere's approach utilizes ultraviolet light to achieve sterility. This not only promises substantial reductions in both capital expenditure (CAPEX) and operational expenditure (OPEX) but also enables the design of more compact and efficient biomanufacturing units. The company, founded in 2022 by Dr. Brian Heligman and Arye Lipman, aims to revolutionize bioprocessing by making it more accessible and cost-effective.

This DoD initiative will focus on creating a prototype bioreactor that can operate continuously. Key features will include advanced UV sterilization protocols, integrated water and media recycling systems, and streamlined downstream processing. Biosphere recently bolstered its capabilities through a strategic acquisition of intellectual property from a gas fermentation company, which will be instrumental in developing the 'protein from air' technology for this project. This move allows Biosphere to leverage existing expertise in gas fermentation, a field known for its potential but also its technical complexities.

Gas fermentation, which uses gases like hydrogen, carbon monoxide, and carbon dioxide as microbial feedstocks instead of sugars, presents unique engineering challenges. These include optimizing gas-liquid mass transfer and ensuring safety when handling gaseous inputs. While companies like LanzaTech and Air Protein have explored this area for fuels, chemicals, and food ingredients, scaling the technology cost-effectively remains a hurdle. Biosphere's UV-sterilization approach could mitigate some of these challenges by simplifying reactor design and reducing operational overhead, potentially making gas fermentation more commercially viable.

The market for alternative protein production is experiencing rapid growth, driven by increasing global demand for sustainable food sources and novel materials. The biomanufacturing sector, valued in the tens of billions of dollars and projected to expand significantly, is seeing substantial investment in enabling technologies. Biosphere's focus on reducing the cost and complexity of bioprocessing positions it to capture a significant share of this expanding market, offering a critical 'picks and shovels' solution for the burgeoning bioeconomy. The DoD funding provides a unique opportunity to advance more experimental bioreactor designs that might be difficult to pursue with purely private capital.

Biosphere's technology is not limited to defense applications. The company envisions its UV-sterilized bioreactors serving a broad range of industries, from food and feed production to advanced materials and therapeutics. By enabling more robust, automated, and low-maintenance biomanufacturing systems, Biosphere aims to unlock new economic efficiencies and accelerate the adoption of bio-based products across various sectors. The company has already demonstrated its technology at benchtop and pilot scales and is currently developing a 20,000-liter demonstration facility.